Drugs / PF-07799544
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07578636 | May → Jul 2026 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT07563894 | Apr → Jun 2026 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05538130 | Nov 2022 → Aug 2027 expected | brain neoplasm, differentiated thyroid carcinoma, low grade glioma, malignant glioma +2 | Pfizer | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07799544 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07563894 ↗ |
| Route | Oral | “Both study medicines are tablets that are taken by mouth at home twice a day.” NCT05538130 ↗ |